List Of Biosimilars Approved In Europe, Jan 22, 2026 · For biosimilar approvals, 2025 was the year of denosumab.

List Of Biosimilars Approved In Europe, Feb 25, 2025 · On 12 December 2024, an aflibercept biosimilar, Celltrion’s Eydenzelt/CT-P42, received a positive opinion during the EMA’s CHMP meeting, pending EC approval. Active principle, indication and date of approval. In January and February 2025, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the granting of an EU-wide marketing authorisation for seven new medicines (Table 1) and three new biosimilar products (Table 2). Jan 22, 2026 · For biosimilar approvals, 2025 was the year of denosumab. Biosimilar medicines authorized by the European Commission. This framework means that biosimilars can only be approved centrally via the European Medicines Agency (EMA) and not nationally. , eight biosimilars were approved for both Prolia® (60 mg pre-filled syringe) and Xgeva® (120 mg vial). Dec 2, 2024 · The table below shows EU regulatory developments in the biosimilars area in 2018-24. The latest update of the table, compiled European Medicines Agency Jan 14, 2025 · Sandoz’s filgrastim biosimilar, Zarxio®, received the first U. Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. Despite the FDA’s relatively slower biosimilar approval pace, the U. In the first four months of 2025, Europe and the U. Highlights include groundbreaking treatments for Alzheimer’s, cancer, and severe infections, alongside 28 biosimilars enhancing access to affordable therapies. Some biosimilars may be approved at national level, such as some low-molecular weight heparins derived from porcine intestinal mucosa. biosimilar market has managed to grow continuously over the past decade. The CHMP also recommended two new generic medicines and extensions of the indication for 24 medicinal products already authorised in Biosimilar medicines authorized by the European Commission. are nearly equivalent in the number of biosimilar approvals, having authorized 12 and 10 biosimilars, respectively. May 5, 2017 · A biosimilar is a biological medicine highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilar Medicines in the EU: Approval Overview 170 A total of Marketing Authorisation applications* have been submitted for evaluation in the EU Apr 28, 2025 · In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This brings the total number of aflibercept biosimilars approved in Europe to seven. approval in 2015, whereas nine filgrastim biosimilars have been approved in Europe dating back to multiple authorizations in 2008. In the European Union (EU), a legal framework for approving biosimilars was established in 2003. Dec 22, 2025 · This page was last updated December 22, 2025 United States Total Approved: 85 Total Launched: 43 BIOSIMILARS IN THE EU – POSITIVE OPINION As of 10 September 2024 112 biosimilars received positive opinion, of which: May 5, 2025 · In 2024 alone, the FDA approved 19 biosimilars, the most approvals in a single year by either regulatory body to date. In the EU, 12 biosimilars were approved for each product, making denosumab the antibody with the most biosimilars approved to date. S. . Dec 22, 2025 · This page was last updated December 22, 2025 United States Total Approved: 85 Total Launched: 43 Mar 28, 2025 · In January 2025, the European Medicines Agency (EMA) released a report of its key figures for the authorization of new and biosimilar medicines in 2024. 1 day ago · To date, EMA has recommended the approval of 88 biosimilars within the product classes of: 1) human growth hormone; 2) granulocyte colony-stimulating factor; 3) erythropoiesis stimulating agent; 4) insulin; 5) follicle-stimulating hormone (FSH); 6) parathyroid hormone; 7) tumour necrosis factor (TNF)-inhibitor; and 8) Nearly all biosimilars approved for use in the EU have been approved centrally, as they use biotechnology for their production. Oncology remained the dominant therapeutic area. Feb 27, 2025 · The risk management plan for a biosimilar candidate should reflect that of the reference medicinal product in terms of safety concerns, additional pharmacovigilance activities and additional risk 2 days ago · This page includes a chart of the approved biosimilar and interchangeable products. In the U. It covers new product filings with the European Medicines Agency, opinions from the EMA’s drug evaluation committee, the CHMP, withdrawals of marketing authorization applications (MAAs), and decisions on biosimilar marketing authorizations by the European Commission. vg99, nq8ggp8, 0tk0, onx, bphenc, fpo, njpffb, hf, bew, bp,